A bright future for osteoporosis treatment.
Osteoporosis is a serious and common condition with very high associated healthcare costs. However, methods for earlier detection and more effective treatment appear likely to produce significant improvement both in the immediate future and in the longer term. Introduction of biological markers of bone turnover should greatly assist in the conduct and evaluation of clinical trials. In addition, a number of very novel approaches are also under investigation that could lead to the introduction of new agents with a wide range of mechanisms of action. These developments were discussed at the Second Joint Meeting of the European Calcified Tissue Society and the International Bone and Mineral Society, held June 25-29, 2005, in Geneva, Switzerland.
Jack
David
D
MWEC Ltd., Glasgow, Scotland.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D000077557:Ibandronic Acid; D018020:Lithium Compounds / Q000627:therapeutic use; D010012:Osteogenesis; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy*; D043884:Receptor, Cannabinoid, CB1 / Q000235:genetics / Q000378:metabolism; D000068296:Risedronic Acid
D000319:Adrenergic beta-Antagonists; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D018020:Lithium Compounds; D043884:Receptor, Cannabinoid, CB1; D000068296:Risedronic Acid; D012968:Etidronic Acid; D000077557:Ibandronic Acid